Literature DB >> 24767804

What do we know about survivorship after treatment for extremity sarcoma? A systematic review.

T Ng Kee Kwong1, S Furtado2, C Gerrand3.   

Abstract

OBJECTIVE: The varied presentations and treatments of extremity bone and soft tissue sarcoma mean that the issues faced by survivors are diverse and complex. The aim of this systematic review was to investigate what is known about this topic with a view to identifying areas for further research or service development.
METHODS: This was a review of the English language literature identified from Medline and Ovid and hand searches published between January 2000 and September 2012. Results were compiled according to physical, psychological and social domains of survivorship.
RESULTS: Of 182 studies identified, 22 met the inclusion criteria. There is a wide range of outcome measures used and a need for more objective measures. Unsurprisingly, survivors of extremity sarcoma typically demonstrate lower levels of physical functioning than healthy controls. In addition, survivors demonstrate a substantial psychological morbidity.
CONCLUSIONS: Services for survivors of extremity sarcoma should include rehabilitation and psychological support, sexual health services, expert pain management, and support to return to work.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bone cancer; Extremity; Quality of life; Sarcoma; Soft tissue sarcoma; Survivorship

Mesh:

Year:  2014        PMID: 24767804     DOI: 10.1016/j.ejso.2014.03.015

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  8 in total

1.  A Prospective Observational Study of Multivisceral Resection for Retroperitoneal Sarcoma: Clinical and Patient-Reported Outcomes 1 Year After Surgery.

Authors:  Marco Fiore; Cinzia Brunelli; Rosalba Miceli; Michele Manara; Susanna Lenna; Nicolò N Rampello; Dario Callegaro; Chiara Colombo; Stefano Radaelli; Sandro Pasquali; Augusto T Caraceni; Alessandro Gronchi
Journal:  Ann Surg Oncol       Date:  2020-11-11       Impact factor: 5.344

2.  Mas-related G-protein-coupled receptor c agonist bovine adrenal medulla 8-22 attenuates bone cancer pain in mice.

Authors:  Yu-E Sun; Cui-E Lu; Yishan Lei; Yue Liu; Zhengliang Ma; Xiaoping Gu
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 3.  UK guidelines for the management of soft tissue sarcomas.

Authors:  Adam Dangoor; Beatrice Seddon; Craig Gerrand; Robert Grimer; Jeremy Whelan; Ian Judson
Journal:  Clin Sarcoma Res       Date:  2016-11-15

Review 4.  A Critical Review of the Impact of Sarcoma on Psychosocial Wellbeing.

Authors:  Lesley Storey; Lorna A Fern; Ana Martins; Mary Wells; Lindsey Bennister; Craig Gerrand; Maria Onasanya; Jeremy S Whelan; Rachael Windsor; Julie Woodford; Rachel M Taylor
Journal:  Sarcoma       Date:  2019-02-17

5.  Qualitative study exploring patients experiences of being diagnosed and living with primary bone cancer in the UK.

Authors:  Ana Martins; Jeremy S Whelan; Lindsey Bennister; Lorna A Fern; Craig Gerrand; Maria Onasanya; Lesley Storey; Mary Wells; Rachael Windsor; Julie Woodford; Rachel M Taylor
Journal:  BMJ Open       Date:  2019-09-24       Impact factor: 2.692

Review 6.  Rehabilitation to Improve the Function and Quality of Life of Soft Tissue and Bony Sarcoma Patients.

Authors:  Cody C Andrews; Geoffrey Siegel; Sean Smith
Journal:  Patient Relat Outcome Meas       Date:  2019-12-31

7.  Cancer Survivors' Disability Experiences and Identities: A Qualitative Exploration to Advance Cancer Equity.

Authors:  Susan Magasi; Hilary K Marshall; Cassandra Winters; David Victorson
Journal:  Int J Environ Res Public Health       Date:  2022-03-06       Impact factor: 3.390

8.  Financial toxicity in sarcoma patients and survivors in Germany: results from the multicenter PROSa study.

Authors:  Matthias Büttner; Susanne Singer; Leopold Hentschel; Stephan Richter; Peter Hohenberger; Bernd Kasper; Dimosthenis Andreou; Daniel Pink; Kathy Taylor; Karin Arndt; Martin Bornhäuser; Jochen Schmitt; Markus K Schuler; Martin Eichler
Journal:  Support Care Cancer       Date:  2021-07-11       Impact factor: 3.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.